Erbitux (cetuximab)

P1/2, N=40, Recruiting, Novartis Pharmaceuticals | Not yet recruiting --> Recruiting

Toripalimab combined with cetuximab demonstrated manageable safety and promising efficacy for R/M HNSCC, warranting further investigation. Clinical trial number: NCT04856631.

Using tumor necrosis factor-α to activate this pathway, we observed enhanced internalization of cetuximab-monomethyl auristatin E and increased cytotoxicity in vitro. Notably, we also found that cisplatin, the backbone of lung cancer chemotherapy, induces a similar noncanonical endocytic response, further supporting the physiological relevance of this pathway. Collectively, our results highlight noncanonical endocytosis as a tractable mechanism to enhance the intracellular delivery and antitumor activity of EGFR-targeted ADCs. This mechanistic insight provides a foundation for developing improved platforms and combination regimens capable of overcoming resistance in NSCLC.

These findings highlight the potential of red blood cell-derived extracellular vesicles as a biocompatible delivery system enabling combined therapy and offering a promising strategy to overcome current limitations in TNBC treatment.

P1, N=24, Suspended, City of Hope Medical Center | Recruiting --> Suspended

P1, N=267, Recruiting, Pfizer | Trial completion date: Aug 2030 --> Oct 2029 | Trial primary completion date: Feb 2029 --> Apr 2028

P1/2, N=90, Recruiting, Isofol Medical AB | Trial completion date: Mar 2029 --> Dec 2029 | Trial primary completion date: Mar 2028 --> Nov 2028 | N=60 --> 90

P3, N=400, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Jul 2029 --> Jul 2030 | Trial primary completion date: Apr 2026 --> Dec 2027

Lenvatinib-pembrolizumab did not improve OS compared with SOC. More participants discontinued lenvatinib-pembrolizumab and lenvatinib monotherapy than SOC. Further research is needed to determine effective second-line treatments for this population.

Current evidence supports DNA methylation as a promising refinement biomarker, but not yet as a stand-alone decision tool. Prospective validation, assay standardization, and integration with ctDNA-guided resistance assessment are required before routine implementation.

The recent approval of encorafenib, cetuximab, and FOLFOX based on the phase III BREAKWATER trial has introduced a new standard of care for the first-line treatment of BRAF V600E-mutated metastatic colorectal cancer (mCRC)...The patient then successfully underwent complete surgical resection of his primary tumor and metastatic disease with negative margins. This case highlights the importance of considering encorafenib-based therapy in select patients with BRAF V600E-mutated mCRC in the setting of compromised liver function.

P2, N=7, Active, not recruiting, Northwestern University | Recruiting --> Active, not recruiting | N=43 --> 7 | Trial primary completion date: Jul 2028 --> May 2026